COMPARE · Reviewed July 30, 2026
ANIP vs CDNA
Verdict: Side-by-side breakdown using the Bull Rankings model. ANIP scored 84.2, CDNA scored 83.8 — ANIP leads.
Compare another set
ANIP
ANI Pharmaceuticals, Inc.
84.2
$80.43 · $1.8B
fundamentals as of
Score gap
0.4
ANIP leads
CDNA
CareDx, Inc.
83.8
$38.10 · $2.0B
fundamentals as of
The model, pillar by pillar (0–100 each)
ANIP
stronger →← stronger
CDNA
64
Qualityreturns · margins · balance sheet
88
100
Growthrevenue & earnings expansion
94
93
Valuevaluation vs sector peers
72
ANIP is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ANIP
CDNA
$191mC
FCF
$92mC-
+37.0%A
Rev
+34.4%A
1.12C
D/E
0.08B+
20.6xB+
P/E
—
0.47A
PEG
—
—
P/S
4.3xB
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ANIP
CDNA
49% below
Price vs fair valuelower is cheaper
71% above
~-7%/yr
Growth the price implies10-yr FCF · lower = less priced in
~28%/yr
+71%
1-yr DCF upside
-53%
+97%
5-yr DCF upside
-42%
+142%
10-yr DCF upside
-22%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ANIP
No notable signals flagged.
CDNA
Why this score
- Buying back stock
The companies
ANIPANI Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.8b. 19% off the 52-week high of $99.50. Revenue growing +37% — in hypergrowth territory. PEG 0.47 — paying under fair value for the growth rate. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $110.00 (implying +37% upside).
Moat
ROE 16% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
CDNACareDx, Inc.
Why now
Diagnostics & Research · market cap $2.0b. 6% off the 52-week high of $40.47. Revenue growing +34% — in hypergrowth territory. 5 sell-side analysts rate this a Buy with a mean 1-yr target of $35.40 (implying -7% upside).
Moat
Net margin 24% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 26% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk
Beta 2.43 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.